NASDAQ:ADMA

ADMA Biologics Competitors

$1.76
-0.11 (-5.88 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.75
Now: $1.76
$1.85
50-Day Range
$1.67
MA: $2.12
$2.64
52-Week Range
$1.57
Now: $1.76
$4.20
Volume1.57 million shs
Average Volume3.63 million shs
Market Capitalization$213.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Competitors

ADMA Biologics (NASDAQ:ADMA) Vs. CLLS, TCRR, ORTX, ALGS, TSHA, and ADAP

Should you be buying ADMA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to ADMA Biologics, including Cellectis (CLLS), TCR2 Therapeutics (TCRR), Orchard Therapeutics (ORTX), Aligos Therapeutics (ALGS), Taysha Gene Therapies (TSHA), and Adaptimmune Therapeutics (ADAP).

Cellectis (NASDAQ:CLLS) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Cellectis and ADMA Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
ADMA Biologics-166.01%-98.83%-37.21%

Insider & Institutional Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 48.9% of ADMA Biologics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 11.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Cellectis has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Cellectis and ADMA Biologics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis00403.00
ADMA Biologics00503.00

Cellectis presently has a consensus price target of $34.6667, indicating a potential upside of 74.03%. ADMA Biologics has a consensus price target of $7.80, indicating a potential upside of 343.18%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Cellectis.

Valuation and Earnings

This table compares Cellectis and ADMA Biologics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million37.07$-102,090,000.00($2.41)-8.27
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91

ADMA Biologics has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

ADMA Biologics beats Cellectis on 7 of the 13 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares TCR2 Therapeutics and ADMA Biologics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-4.77
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91

TCR2 Therapeutics has higher earnings, but lower revenue than ADMA Biologics. TCR2 Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for TCR2 Therapeutics and ADMA Biologics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00803.00
ADMA Biologics00503.00

TCR2 Therapeutics currently has a consensus target price of $43.2857, suggesting a potential upside of 96.57%. ADMA Biologics has a consensus target price of $7.80, suggesting a potential upside of 343.18%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than TCR2 Therapeutics.

Volatility and Risk

TCR2 Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500.

Insider and Institutional Ownership

82.1% of TCR2 Therapeutics shares are owned by institutional investors. Comparatively, 48.9% of ADMA Biologics shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by company insiders. Comparatively, 11.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares TCR2 Therapeutics and ADMA Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
ADMA Biologics-166.01%-98.83%-37.21%

Summary

TCR2 Therapeutics beats ADMA Biologics on 8 of the 12 factors compared between the two stocks.

ADMA Biologics (NASDAQ:ADMA) and Orchard Therapeutics (NASDAQ:ORTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

48.9% of ADMA Biologics shares are owned by institutional investors. Comparatively, 66.6% of Orchard Therapeutics shares are owned by institutional investors. 11.7% of ADMA Biologics shares are owned by insiders. Comparatively, 4.2% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ADMA Biologics and Orchard Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
Orchard TherapeuticsN/A-65.65%-47.92%

Valuation & Earnings

This table compares ADMA Biologics and Orchard Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91
Orchard Therapeutics$2.51 million331.66$-163,420,000.00($1.75)-3.85

ADMA Biologics has higher revenue and earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ADMA Biologics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Orchard Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ADMA Biologics and Orchard Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Orchard Therapeutics00403.00

ADMA Biologics presently has a consensus price target of $7.80, suggesting a potential upside of 343.18%. Orchard Therapeutics has a consensus price target of $14.75, suggesting a potential upside of 119.17%. Given ADMA Biologics' higher possible upside, research analysts clearly believe ADMA Biologics is more favorable than Orchard Therapeutics.

Summary

ADMA Biologics beats Orchard Therapeutics on 9 of the 13 factors compared between the two stocks.

ADMA Biologics (NASDAQ:ADMA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Earnings and Valuation

This table compares ADMA Biologics and Aligos Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than ADMA Biologics.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ADMA Biologics and Aligos Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Aligos Therapeutics00403.00

ADMA Biologics presently has a consensus price target of $7.80, suggesting a potential upside of 343.18%. Aligos Therapeutics has a consensus price target of $35.75, suggesting a potential upside of 66.51%. Given ADMA Biologics' higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Aligos Therapeutics.

Profitability

This table compares ADMA Biologics and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
Aligos TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

48.9% of ADMA Biologics shares are held by institutional investors. 11.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ADMA Biologics beats Aligos Therapeutics on 5 of the 8 factors compared between the two stocks.

ADMA Biologics (NASDAQ:ADMA) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

48.9% of ADMA Biologics shares are held by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are held by institutional investors. 11.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ADMA Biologics and Taysha Gene Therapies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91
Taysha Gene TherapiesN/AN/AN/AN/AN/A

Taysha Gene Therapies has lower revenue, but higher earnings than ADMA Biologics.

Profitability

This table compares ADMA Biologics and Taysha Gene Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
Taysha Gene TherapiesN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for ADMA Biologics and Taysha Gene Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Taysha Gene Therapies00603.00

ADMA Biologics currently has a consensus target price of $7.80, indicating a potential upside of 343.18%. Taysha Gene Therapies has a consensus target price of $40.50, indicating a potential upside of 91.13%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Taysha Gene Therapies.

ADMA Biologics (NASDAQ:ADMA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares ADMA Biologics and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
Adaptimmune Therapeutics-3,858.14%-44.94%-33.70%

Analyst Recommendations

This is a breakdown of current ratings and target prices for ADMA Biologics and Adaptimmune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Adaptimmune Therapeutics03202.40

ADMA Biologics currently has a consensus target price of $7.80, indicating a potential upside of 343.18%. Adaptimmune Therapeutics has a consensus target price of $15.50, indicating a potential upside of 206.93%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADMA Biologics is more favorable than Adaptimmune Therapeutics.

Institutional & Insider Ownership

48.9% of ADMA Biologics shares are owned by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are owned by institutional investors. 11.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares ADMA Biologics and Adaptimmune Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million7.27$-48,280,000.00($0.92)-1.91
Adaptimmune Therapeutics$1.12 million700.99$-137,160,000.00($1.32)-3.83

ADMA Biologics has higher revenue and earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ADMA Biologics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.

Summary

ADMA Biologics beats Adaptimmune Therapeutics on 8 of the 14 factors compared between the two stocks.


ADMA Biologics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cellectis logo
CLLS
Cellectis
1.3$19.92-1.6%$852.18 million$22.99 million-10.60News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02-2.8%$839.78 millionN/A-9.10News Coverage
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.73-3.7%$832.47 million$2.51 million-4.08Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.47-5.4%$818.93 millionN/A0.00Lockup Expiration
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$21.19-6.0%$800.16 millionN/A0.00Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.05-1.6%$785.11 million$1.12 million-5.10
Inhibrx logo
INBX
Inhibrx
1.6$20.50-0.4%$773.83 millionN/A0.00
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$22.67-0.3%$734.76 million$5.78 million-10.64
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.08-2.3%$708.25 millionN/A0.00Analyst Upgrade
News Coverage
Gap Up
Vaxart logo
VXRT
Vaxart
1.3$5.53-2.5%$651.25 million$9.86 million-9.37Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.74-3.3%$630.67 million$14.75 million-2.46
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.35-3.3%$590.92 million$13.29 million-9.47News Coverage
Gap Down
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.56-1.2%$585.57 millionN/A0.00Analyst Downgrade
Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.42-0.0%$576.10 million$17.80 million-22.76Analyst Report
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.21-3.1%$556.83 millionN/A-2.53Gap Down
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.90-0.6%$552.76 millionN/A-1.30Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.48-2.5%$530.64 millionN/A-5.90Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.60-3.6%$490.08 million$22.24 million-4.28Gap Down
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$13.23-5.1%$474.60 millionN/A0.00Analyst Report
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32-2.5%$471.16 millionN/A-3.43News Coverage
Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.25-1.5%$466.41 millionN/A-8.20
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.10-1.4%$445.46 million$4.36 million-3.18Analyst Upgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.78-6.6%$443.95 million$147.87 million-3.25Gap Down
Opthea logo
OPT
Opthea
1.5$9.66-1.2%$419.80 millionN/A0.00Lockup Expiration
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$9.51-6.4%$397.95 millionN/A0.00Analyst Report
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.66-1.0%$380.70 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.19-2.7%$380.20 million$8.15 million-1.75
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.27-2.3%$348.11 million$250,000.00-3.31News Coverage
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.49-6.2%$340.69 millionN/A0.00Lockup Expiration
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.26-2.1%$336.50 million$96.12 million-12.53Analyst Revision
News Coverage
Gap Down
Surface Oncology logo
SURF
Surface Oncology
1.3$7.95-2.8%$331.74 million$15.36 million-12.05News Coverage
Gap Down
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.60-3.4%$293.14 million$2.91 million-1.95Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$8.40-1.8%$284.77 millionN/A-3.46
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$2.03-1.0%$283.79 million$4.13 million-4.51
PDL BioPharma logo
PDLI
PDL BioPharma
0.8$2.47-0.0%$282.14 million$54.76 million-2.19
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.76-0.7%$258.92 millionN/A-7.85
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$10.57-0.9%$228.50 millionN/A0.00
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.16-2.9%$197.28 millionN/A-3.85Gap Down
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.83-3.2%$189.64 millionN/A-5.48Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.41-3.6%$188.54 million$2.45 million-2.07Gap Down
Genfit logo
GNFT
Genfit
1.3$4.62-0.4%$179.53 million$45.88 million-2.35Analyst Upgrade
Analyst Revision
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.76-0.2%$179.23 million$104.39 million-2.90News Coverage
INmune Bio logo
INMB
INmune Bio
1.5$11.77-3.2%$175.76 millionN/A-12.13News Coverage
Gap Up
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.95-3.3%$167.87 millionN/A0.00Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$4.34-5.5%$163.58 millionN/A-2.02Gap Down
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.28-2.2%$163.30 millionN/A-7.66News Coverage
Gap Down
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.02-4.8%$156.80 millionN/A-2.82Gap Down
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.32-0.5%$151.58 million$32.12 million-87.08News Coverage
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.73-1.1%$149.13 million$20,000.000.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.